Artificial intelligence for medication-related osteonecrosis of the jaw: a scoping review
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology · 2025-10 · 140 (4) · 405-415
DOI: 10.1016/j.oooo.2025.03.004 ↗Kurz gefasst
Scoping Review in der Zeitschrift Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2025-10. Verfasst von Yuichi Mine und 5 weiteren Autor:innen. Beteiligte Einrichtung: Project Research Center for Integrating Digital Dentistry, Hiroshima University, Hiroshima, Japan; Department of Medical Systems Engineering, Graduat…. Hauptthemen laut MEDLINE: Artificial Intelligence, Bisphosphonate-Associated Osteonecrosis of the Jaw. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan, Government of Japan Ministry of Education Culture Sports Science and Technology.
Abstract (Originalsprache)
OBJECTIVES: To describe the current state of research on the application of artificial intelligence (AI) to the prediction, diagnosis, and management of medication-related osteonecrosis of the jaw (MRONJ). STUDY DESIGN: A scoping review was conducted using PubMed/MEDLINE, Scopus, and Web of Science databases through March 1, 2024, and updated to December 31, 2024, according to PRISMA-SCR guidelines. Data on AI tasks, models, patient information, datasets, and performance metrics were extracted from eligible studies. RESULTS: Eight studies met the inclusion criteria, focusing on MRONJ onset prediction (n = 5), diagnosis (n = 2), and patient education (n = 1). For onset prediction, machine learning models (support vector machines, random forests, gradient boosting machines) achieved area under the curve values of 0.793-0.973. For diagnosis, deep learning models using radiographic images achieved 96% accuracy with 93% precision and recall. For patient education, a large language model was evaluated with moderate to high response quality. CONCLUSIONS: While AI shows promise in the prediction and diagnosis of MRONJ, challenges related to data quality, validation, and clinical integration need to be addressed. Future research should focus on developing standardized, explainable AI models and establishing implementation guidelines for clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Project Research Center for Integrating Digital Dentistry, Hiroshima University, Hiroshima, Japan; Department of Medical Systems Engineering, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiro…
- Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Oral and Maxillofacial Radiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Förderung
- Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan
- Government of Japan Ministry of Education Culture Sports Science and Technology
Zitieren
APA
Mine, Y., Okazaki, S., Yamasaki, S., Kakimoto, N., Yanamoto, S., & Murayama, T. (2025). Artificial intelligence for medication-related osteonecrosis of the jaw: a scoping review. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 140(4), 405-415. https://doi.org/10.1016/j.oooo.2025.03.004
Vancouver
Mine Y, Okazaki S, Yamasaki S, Kakimoto N, Yanamoto S, Murayama T. Artificial intelligence for medication-related osteonecrosis of the jaw: a scoping review. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2025;140(4):405-415. doi:10.1016/j.oooo.2025.03.004
BibTeX
@article{Mine2025,
author = {Mine, Yuichi and Okazaki, Shota and Yamasaki, Sachiko and Kakimoto, Naoya and Yanamoto, Souichi and Murayama, Takeshi},
title = {Artificial intelligence for medication-related osteonecrosis of the jaw: a scoping review},
journal = {Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology},
year = {2025},
volume = {140},
number = {4},
pages = {405--415},
doi = {10.1016/j.oooo.2025.03.004}
}
EUVIMED